Company Overview
Company Type: Public Company
Website: www.waverleypharma.com
Number of Employees: -
Ticker: WAVE (TSXV)
Year Founded: -


Business Description
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes cancer therapeutics in the United Kingdom. It focuses on the generic oncology injectable products. The company sells generic oncology products comprising capecitabine, temozolomide, and erlotinib. Its products under development include injectable generic chemotherapy drugs, such as Pemetrexed for the treatment of non-small cell lung cancer and other indications; and Bortezomib to treat multiple myeloma and other indications. Waverley Pharma Inc. is headquartered in Winnipeg, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.8
Market Capitalization
1.4
TEV/Total Revenue
2.8x
EBITDA
(0.9)
Total Enterprise Value
2.2
TEV/EBITDA
NM
EBIT
(1.2)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(0.9)
Total Debt
0.9
Price/Tang BV
NM
Total Assets
2.2
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-03-2023

Key Professionals
Name
Title
Thiessen, Larry 
President & CEO
Uddin, Haaris 
Chief Financial Officer

Key Board Members
Name
Title
Friesen, Albert David
Chairman of the Board
Enns, P. Marcus
Independent Director
Siwanowicz, Hellen L.
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
4-1250 Waverley Street | Winnipeg, MB | R3T 6C6 | Canada
Phone: 204-928-7907   

Prior Investors
PenderFund Capital Management Ltd.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.03
Market Cap (mm)
1.4
Open
 0.03
Shares Out. (mm)
54.0
Previous Close
 0.03
Float %
25.2%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.03/ 0.03
Diluted EPS Excl. Extra Items
(0.02)
52 wk High/Low
 0.08/ 0.02
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0090
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
1.21


 
Delayed Quote** | Last Updated on Oct-03-2023 12:00 AM (GMT-5)
TSXV:WAVE - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Buffalo Capital Inc.
As of October 24, 2017, Buffalo Capital Inc. was acquired by Waverley Pharma Inc., in a reverse merger transaction. Buffalo Capital Inc. does not have significant operations. It focuses on identification and evaluation of companies, businesses, or assets with a view to completing a proposed qualifying transaction. The company was incorporated in 2016 and is headquartered in Winnipeg, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00
Waverley Pharma Europe Limited

Europe
-
-
-
-
Waverley Pharma International Inc.

Latin America and Caribbean
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-09-2017
Oct-24-2017
Merger/Acquisition
Buyer
Buffalo Capital Inc.
Waverley Pharma Inc. (TSXV:WAVE)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-21-2023
Annual General Meeting
Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023
Apr-27-2023
Auditor Going Concern Doubts
Waverley Pharma Inc. Auditor Raises 'Going Concern' Doubt
Jan-11-2023
Product-Related Announcements
Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor Program
Jun-15-2022
Annual General Meeting
Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022
Apr-29-2022
Auditor Going Concern Doubts
Waverley Pharma Inc. Auditor Raises 'Going Concern' Doubt

M&A Advisors
Field LLP


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Field LLP


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Wright Investors' Service Inc.

May 24, 2023 01:41 AM
WAVE
Flow of Funds Report for Waverley Pharma Inc - prepared by Wright Investors Service
Notes
66


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Friesen Ph.D., Albert David

40,292,000

74.61

1.0

May-08-2023


Enns, P. Marcus

100,000

0.19

0.0

May-08-2023



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
WAV-101 (Future), WAV-102 (Future), WAV-103 (Future), WAV-104 (Future), WAV-105 (Future), WAV-106 (Future), WAV-107 (Future), WAV-108 (Future)


Upcoming Events
Date/Time
Type
Nov-24-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-16-2023
Jun-30-2023
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Interim Financial Statements
280 KB
Aug-02-2023
-
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
News Releases
44 KB
May-29-2023
-
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Management Proxy Materials
69 KB
May-29-2023
-
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Management Proxy Materials
253 KB
May-29-2023
-
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Management Proxy Materials
532 KB
May-25-2023
Mar-31-2023
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Interim Financial Statements
274 KB
Apr-27-2023
Dec-31-2022
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Annual Financial Statements
195 KB
Apr-27-2023
Dec-31-2022
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Annual Financial Statements
2 MB
Apr-27-2023
Dec-31-2022
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Annual Financial Statements
155 KB
Apr-13-2023
-
Waverley Pharma Inc. (TSXV:WAVE)
SEDAR
Notice of the Meeting and Record Date
313 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Uddin B.Com., CPA, Haaris  (Chief Financial Officer)
Apr-01-2021
Common Shares
6,800
1,078
Open Market Acquisition
30.91
Exchange Announcement
Friesen Ph.D., Albert David (Chairman of the Board)
Nov-23-2020
Common Shares
10,000
1,102
Open Market Acquisition
0.02
Exchange Announcement
Uddin B.Com., CPA, Haaris  (Chief Financial Officer)
Sep-21-2020
Common Shares
12,000
1,920
Open Market Acquisition
120.00
Exchange Announcement
Friesen Ph.D., Albert David (Chairman of the Board)
Aug-30-2019
Common Shares
5,000
516
Open Market Acquisition
0.01
Exchange Announcement
Friesen Ph.D., Albert David (Chairman of the Board)
Aug-14-2019
Common Shares
10,500
1,290
Open Market Acquisition
0.03
Exchange Announcement
-
Aug-14-2019
Common Shares
500
52
Open Market Acquisition
-
Exchange Announcement
-
Aug-14-2019
Common Shares
10,000
1,238
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Friesen, Albert David
Chairman of the Board
888-435-2220
(204) 488-9823

Enns, P. Marcus
Independent Director
(204) 477-7595
-

Siwanowicz, Hellen L.
Independent Director
(416) 307-4032
(416) 365-1719
hsiwanowicz@langmichener.ca
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Thiessen, Larry 
President & CEO
204-928-7907
-
-
Uddin, Haaris 
Chief Financial Officer
(204) 478-5609
-
huddin@waverleypharma.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
